© 1995 American Heart Association, Inc.
Articles |
Regression of Atherosclerosis in Female Monkeys
From the Comparative Medicine Clinical Research Center and Departments of Comparative Medicine (J.K.W., M.S.A., E.K.H., T.C.R., T.B.C.) and Public Health Sciences (T.M.M.), and the Division of Cardiology (D.M.H.), Bowman Gray School of Medicine of Wake Forest University, Winston-Salem, NC.
Correspondence to J. Koudy Williams, DVM, Department of Comparative Medicine, Bowman Gray School of Medicine of Wake Forest University, Medical Center Blvd, Winston-Salem, NC 27157-1040.
Abstract The objective of this study was to determine the structural and functional changes that occur in the artery wall in response to plasma lipid lowering and hormone replacement in surgically postmenopausal monkeys with established coronary artery atherosclerosis. Eighty-eight surgically postmenopausal cynomolgus monkeys were fed an atherogenic diet for 24 months and were then allocated into 4 groups: group 1 (n=20), a baseline necropsy group; group 2 (n=25), a lipid-lowering diet only; group 3 (n=22), lipid lowering plus conjugated equine estrogen treatment equivalent to 0.625 mg/d for a woman; and group 4 (n=21), lipid lowering plus conjugated equine estrogen and medroxyprogesterone acetate treatment (equivalent to 2.5 mg/d for a woman). Treatment was for 30 months. Histomorphometric analysis of perfusion-fixed coronary arteries revealed that plaque size did not change significantly in any of the groups compared with group 1 (P>.20). Plasma lipid lowering permitted coronary artery remodeling to occur (coronary artery and lumen size doubled compared with group 1) (P<.05); however, hormone therapy did not augment remodeling. Quantitative angiographic analysis of coronary artery reactivity revealed that lipid lowering improved dilator responses to acetylcholine by 22±4% (P=.01) but not to nitroglycerin (P=.23). Hormone replacement did not further affect vascular reactivity to the agonists tested (P>.4), but addition of medroxyprogesterone acetate diminished the beneficial effects of conjugated estrogens on coronary flow reserve (P=.03). In summary, the major arterial sequelae of lipid lowering in female monkeys were artery and lumen enlargement and improved reactivity of large epicardial coronary arteries. Addition of hormone replacement to the dietary modification did not further augment these improvements, except for the dilator capacity of the coronary microcirculation.
Key Words: atherosclerosis • estrogen • females • progestin • regression
This article has been cited by other articles:
 |
|
 |
|
  C. A. Shively, T. C. Register, M. R. Adams, D. L. Golden, S. L. Willard, and T. B. Clarkson Depressive Behavior and Coronary Artery Atherogenesis in Adult Female Cynomolgus Monkeys Psychosom Med, July 1, 2008; 70(6): 637 - 645. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Pinna, A. Cignarella, P. Sanvito, V. Pelosi, and C. Bolego Prolonged Ovarian Hormone Deprivation Impairs the Protective Vascular Actions of Estrogen Receptor {alpha}Agonists Hypertension, April 1, 2008; 51(4): 1210 - 1217. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. E. Van Pelt, R. S. Schwartz, and W. M. Kohrt Insulin Secretion and Clearance after Subacute Estradiol Administration in Postmenopausal Women J. Clin. Endocrinol. Metab., February 1, 2008; 93(2): 484 - 490. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Booth, N. R. Obeid, and B. R. Lucchesi Activation of estrogen receptor-{alpha} protects the in vivo rabbit heart from ischemia-reperfusion injury Am J Physiol Heart Circ Physiol, November 1, 2005; 289(5): H2039 - H2047. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. V. Nair, D. Waters, W. Rogers, G. J. Kowalchuk, T. D. Stuckey, and D. M. Herrington Pulse Pressure and Coronary Atherosclerosis Progression in Postmenopausal Women Hypertension, January 1, 2005; 45(1): 53 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. K. Dubey, B. Imthurn, L. C. Zacharia, and E. K. Jackson Hormone Replacement Therapy and Cardiovascular Disease: What Went Wrong and Where Do We Go From Here? Hypertension, December 1, 2004; 44(6): 789 - 795. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. K. Koh and I. Sakuma Should Progestins Be Blamed for the Failure of Hormone Replacement Therapy to Reduce Cardiovascular Events in Randomized Controlled Trials? Arterioscler. Thromb. Vasc. Biol., July 1, 2004; 24(7): 1171 - 1179. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Iemolo, A. Martiniuk, D. A. Steinman, and J. D. Spence Sex Differences in Carotid Plaque and Stenosis Stroke, February 1, 2004; 35(2): 477 - 481. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Fitzpatrick Hormones and the Heart: Controversies and Conundrums J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 5609 - 5610. [Full Text] [PDF]
|
|
|
|
|
|
J. M. Muller-Delp, D. B. Lubahn, K. E. Nichol, B. J. Philips, E. M. Price, E. M. Curran, and M. H. Laughlin Regulation of nitric oxide-dependent vasodilation in coronary arteries of estrogen receptor-{alpha}-deficient mice Am J Physiol Heart Circ Physiol, November 1, 2003; 285(5): H2150 - H2157. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. N. Hodis, W. J. Mack, S. P. Azen, R. A. Lobo, D. Shoupe, P. R. Mahrer, D. P. Faxon, L. Cashin-Hemphill, M. E. Sanmarco, W. J. French, et al. Hormone Therapy and the Progression of Coronary-Artery Atherosclerosis in Postmenopausal Women N. Engl. J. Med., August 7, 2003; 349(6): 535 - 545. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Krajewski, T. W. Abel, M. L. Voytko, and N. E. Rance Ovarian Steroids Differentially Modulate the Gene Expression of Gonadotropin-Releasing Hormone Neuronal Subtypes in the Ovariectomized Cynomolgus Monkey J. Clin. Endocrinol. Metab., February 1, 2003; 88(2): 655 - 662. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. Hodgin and N. Maeda Minireview: Estrogen and Mouse Models of Atherosclerosis Endocrinology, December 1, 2002; 143(12): 4495 - 4501. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P. Byington, C. D. Furberg, D. M. Herrington, J. A. Herd, D. Hunninghake, M. Lowery, W. Riley, T. Craven, L. Chaput, C. C. Ireland, et al. Effect of Estrogen Plus Progestin on Progression of Carotid Atherosclerosis in Postmenopausal Women With Heart Disease: HERS B-Mode Substudy Arterioscler. Thromb. Vasc. Biol., October 1, 2002; 22(10): 1692 - 1697. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. A. Sanders, T. S Dean, D. Grainger, G. J Miller, and H. Wiseman Moderate intakes of intact soy protein rich in isoflavones compared with ethanol-extracted soy protein increase HDL but do not influence transforming growth factor {beta}1 concentrations and hemostatic risk factors for coronary heart disease in healthy subjects Am. J. Clinical Nutrition, August 1, 2002; 76(2): 373 - 377. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Herrington, E. Vittinghoff, F. Lin, J. Fong, F. Harris, D. Hunninghake, V. Bittner, H. G. Schrott, R. S. Blumenthal, R. Levy, et al. Statin Therapy, Cardiovascular Events, and Total Mortality in the Heart and Estrogen/Progestin Replacement Study (HERS) Circulation, June 25, 2002; 105(25): 2962 - 2967. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. S Mikkola and T. B Clarkson Estrogen replacement therapy, atherosclerosis, and vascular function Cardiovasc Res, February 15, 2002; 53(3): 605 - 619. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Herrington, M. A. Espeland, J. R. Crouse III, J. Robertson, W. A. Riley, M. A. McBurnie, and G. L. Burke Estrogen Replacement and Brachial Artery Flow-Mediated Vasodilation in Older Women Arterioscler. Thromb. Vasc. Biol., December 1, 2001; 21(12): 1955 - 1961. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Stein and O. Stein Does Therapeutic Intervention Achieve Slowing of Progression or Bona Fide Regression of Atherosclerotic Lesions? Arterioscler. Thromb. Vasc. Biol., February 1, 2001; 21(2): 183 - 188. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Herrington, D. M. Reboussin, K. B. Brosnihan, P. C. Sharp, S. A. Shumaker, T. E. Snyder, C. D. Furberg, G. J. Kowalchuk, T. D. Stuckey, W. J. Rogers, et al. Effects of Estrogen Replacement on the Progression of Coronary-Artery Atherosclerosis N. Engl. J. Med., August 24, 2000; 343(8): 522 - 529. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Mosca The Role of Hormone Replacement Therapy in the Prevention of Postmenopausal Heart Disease Arch Intern Med, August 14, 2000; 160(15): 2263 - 2272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. Teede, B. P. McGrath, J. J. Smolich, E. Malan, D. Kotsopoulos, Y.-L. Liang, and R. E. Peverill Postmenopausal Hormone Replacement Therapy Increases Coagulation Activity and Fibrinolysis Arterioscler. Thromb. Vasc. Biol., May 1, 2000; 20(5): 1404 - 1409. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. J. Teede, Y.-L. Liang, L. M. Shiel, J. J. McNeil, and B. P. McGrath Hormone replacement therapy in postmenopausal women protects against smoking-induced changes in vascular structure and function J. Am. Coll. Cardiol., July 1, 1999; 34(1): 131 - 137. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. W. Abel, M. L. Voytko, and N. E. Rance The Effects of Hormone Replacement Therapy on Hypothalamic Neuropeptide Gene Expression in a Primate Model of Menopause J. Clin. Endocrinol. Metab., June 1, 1999; 84(6): 2111 - 2118. [Abstract] [Full Text]
|
|
|
|
 |
|
 B. A. Walsh, A. E. Mullick, R. L. Walzem, and J. C. Rutledge 17ß-Estradiol reduces tumor necrosis factor-{alpha}-mediated LDL accumulation in the artery wall J. Lipid Res., March 1, 1999; 40(3): 387 - 396. [Abstract] [Full Text]
|
|
|
|
|
|
P. E. Gallagher, P. Li, J. R. Lenhart, M. C. Chappell, and K. B. Brosnihan Estrogen Regulation of Angiotensin-Converting Enzyme mRNA Hypertension, January 1, 1999; 33(1): 323 - 328. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. P. McGrath, Y.-L. Liang, H. Teede, L. M. Shiel, J. D. Cameron, and A. Dart Age-Related Deterioration in Arterial Structure and Function in Postmenopausal Women : Impact of Hormone Replacement Therapy Arterioscler. Thromb. Vasc. Biol., July 1, 1998; 18(7): 1149 - 1156. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. C. Register, M. R. Adams, D. L. Golden, and T. B. Clarkson Conjugated Equine Estrogens Alone, but Not in Combination With Medroxyprogesterone Acetate, Inhibit Aortic Connective Tissue Remodeling After Plasma Lipid Lowering in Female Monkeys Arterioscler. Thromb. Vasc. Biol., July 1, 1998; 18(7): 1164 - 1171. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. C. Harnish, M. J. Evans, M. S. Scicchitano, R. A. Bhat, and S. K. Karathanasis Estrogen Regulation of the Apolipoprotein AI Gene Promoter through Transcription Cofactor Sharing J. Biol. Chem., April 10, 1998; 273(15): 9270 - 9278. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. B. Clarkson, M. S. Anthony, and C. P. Jerome Lack of Effect of Raloxifene on Coronary Artery Atherosclerosis of Postmenopausal Monkeys J. Clin. Endocrinol. Metab., March 1, 1998; 83(3): 721 - 726. [Abstract] [Full Text]
|
|
|
|
|
|
G. Kojda, B. Husgen, A. Hacker, D. Perings, E. M. Schnaith, E. Kottenberg, and E. Noack Impairment of endothelium-dependent vasorelaxation in experimental atherosclerosis is dependent on gender Cardiovasc Res, March 1, 1998; 37(3): 738 - 747. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. B. Brosnihan, P. Li, D. Ganten, and C. M. Ferrario Estrogen protects transgenic hypertensive rats by shifting the vasoconstrictor-vasodilator balance of RAS Am J Physiol Regulatory Integrative Comp Physiol, December 1, 1997; 273(6): R1908 - R1915. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Mosca, J. E. Manson, S. E. Sutherland, R. D. Langer, T. Manolio, E. Barrett-Connor, and E. Barrett-Connor Cardiovascular Disease in Women : A Statement for Healthcare Professionals From the American Heart Association Circulation, October 7, 1997; 96(7): 2468 - 2482. [Full Text]
|
|
|
|
|
|
N. H. Bjarnason, J. Haarbo, I. Byrjalsen, R. F. Kauffman, and C. Christiansen Raloxifene Inhibits Aortic Accumulation of Cholesterol in Ovariectomized, Cholesterol-Fed Rabbits Circulation, September 16, 1997; 96(6): 1964 - 1969. [Abstract] [Full Text]
|
|
|
|
|
|
H. Lou, T. Kodama, Y. J. Zhao, P. Maurice, Y. N. Wang, N. Katz, and M. L. Foegh Inhibition of Transplant Coronary Arteriosclerosis in Rabbits by Chronic Estradiol Treatment Is Associated With Abolition of MHC Class II Antigen Expression Circulation, December 15, 1996; 94(12): 3355 - 3361. [Abstract] [Full Text]
|
|